Circio Holding ASA (OSL:CRNA) Interest Expense : kr-3.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Circio Holding ASA's interest expense for the three months ended in Dec. 2023 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was kr-3.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Circio Holding ASA's Operating Income for the three months ended in Dec. 2023 was kr 0.00 Mil. Circio Holding ASA's Interest Expense for the three months ended in Dec. 2023 was kr 0.00 Mil. Circio Holding ASA has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Circio Holding ASA Interest Expense Historical Data

The historical data trend for Circio Holding ASA's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Interest Expense Chart

Circio Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.02

-4.35

-2.04

-4.99

-3.56

Circio Holding ASA Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.59	-0.97	-2.06	-	-

Circio Holding ASA Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.03 Mil.

Circio Holding ASA (OSL:CRNA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Circio Holding ASA's Interest Expense for the three months ended in Dec. 2023 was kr0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was kr0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was kr0.00 Mil.

Circio Holding ASA's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Circio Holding ASA had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Circio Holding ASA (OSL:CRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

TA50:Germany

Address

Vollsveien 19, Lysaker, Oslo, NOR, 1366

Website

https://www.circio.com

Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines